In the closing segment, the panel looks ahead, both at where the technology is heading and at what will still require human judgment once it gets there. Piotr Alvarez outlines a three-horizon view of artificial intelligence’s (AI) impact on peptide method development. In the near term, he expects AI to narrow the range of conditions…
NTAP provides additional Medicare reimbursement to hospitals using PearlMatrix, the first and only bone growth accelerator demonstrating superior lumbar fusion speed
